Advertisement

Topics

Novartis-Tochter AveXis zeigt positive Daten zur Genersatztherapie Zolgensma

17:17 EDT 16 Apr 2019 | FinanzNachrichten

Basel (awp) - Die Novartis-Tochter AveXis hat mit der Genersatztherapie Zolgensma (AVXS-101) in der Phase-III-Studie STR1VE positive Daten erzielt. Die Therapie habe in der Behandlung von spinaler ...

Original Article: Novartis-Tochter AveXis zeigt positive Daten zur Genersatztherapie Zolgensma

NEXT ARTICLE

More From BioPortfolio on "Novartis-Tochter AveXis zeigt positive Daten zur Genersatztherapie Zolgensma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...